&nbsp;

NewBackgroundRTP.png

Sep 2019

Document

newWindowIconPurple.png

Oct 2019

Blog posts

Just the facts: Answering your questions about cervical screening

Dr. Joan MurphyClinical LeadOntario Cervical Screening Program Are you up to date on your cervical screening? The Ontario Cervical Screening Program...

Oct 2019

Document

NewOHCCO logo

Jan 2020

Neuroendocrine Tumours (NETs)

Regimen

NIVL+IPIL(MNT)

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab plus Ipilimumab - In Combination with Platinum Doublet Chemotherapy for First Line Metastatic or Recurrent Non-Small Cell Lung Cancer

New Drug Funding Program

Nivolumab plus Ipilimumab - In Combination with Platinum Doublet Chemotherapy for First Line Metastatic or Recurrent Non-Small Cell Lung Cancer

Drugs Used:

nivolumab,

ipilimumab

Quick Link(s):

Regimen Monograph

Nov 2024

Document

NursingPracticeContinuum.pdf

Jun 2021

Document

jonathanFoster.jpg

Jul 2021

Regimen

NIVL(MNT)

Cancer Type:

Skin,

Melanoma

Intent: Adjuvant

Drugs Used:

nivolumab (Unfunded)

Quick Link(s):

Regimen Monograph

Aug 2024

Regimen

NPAC(W)+PEMB

Cancer Type:

Breast

Intent: Palliative

Funding:

New Drug Funding Program

Nab-Paclitaxel - Metastatic Breast Cancer

New Drug Funding Program

Pembrolizumab - Locally Recurrent Unresectable or Metastatic Triple Negative Breast Cancer

Drugs Used:

pembrolizumab,

nab-PACLitaxel

Quick Link(s):

Regimen Monograph

May 2024

Regimen

NIVL

Cancer Type:

Gastrointestinal,

Esophagus

Intent: Adjuvant

Funding:

New Drug Funding Program

Nivolumab - Adjuvant Treatment of Completely Resected Esophageal or Esophagogastric Junction Cancer

Drugs Used:

nivolumab